Asst. Prof. Shilpa Gupta discusses the newly defined criteria for “platinum-ineligibility” in patients with metastatic urothelial cancer on behalf of the Platinum-Ineligibility in Bladder Cancer Working Group.


Newly defined criteria for “platinum-ineligible” patients with metastatic urothelial cancer (mUC)

Asst. Prof. Shilpa Gupta discusses results from the Bladder Cancer Working Group survey study. The aim of the study is to define criteria for “platinum-ineligibility” in patients with metastatic urothelial cancer (mUC). Platinum-ineligible mUC patients are those who are ineligible for cisplatin and carboplatin treatment and therefore have limited treatment options. Other treatments such as pembrolizumab and atezolizumab are available but restricted to patients who are either ‘platinum ineligible’ or who have high PD-L1 expression. Therefore, a definition of platinum-ineligibility is necessary when deciding on patient treatments, and for determining patients eligibility for clinical trials.

Methods for defining platinum ineligibility

Presented are data from two rounds of survey among genitourinary oncologists. The threshold of criteria such as age, ECOG performance status, creatinine clearance, peripheral neuropathy grade, and heart failure classification are assessed as possible defining factors for Platinum-Ineligibility. Prof. Gupta concludes 5 specified criteria, any one of which would class a patient as platinum-ineligible and thus receive immunotherapy in place of cisplatin and carboplatin. The video and slides aim to provide practical guidance for urologists and we hope you find it of use to your clinical practice.

Shilpa Gupta, MD is an Associate Professor in the Division of Hematology, Oncology and Transplantation and the lead for the Phase 1 Interdisciplinary Solid Tumor Program at the Masonic Cancer Center, University of Minnesota, Minneapolis, USA. Prior to joining the University of Minnesota in July 2015, Dr Gupta was faculty in Genitourinary Oncology and Experimental Therapeutics at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida for 4 years. Dr Gupta’s clinical and research interests are to treat patients with genitourinary malignancies and develop novel trials using targeted therapies and immunotherapies. She is currently the Principal investigator of several early and late phase trials in genitourinary oncology. Dr Gupta is passionate about her research and has published her research across a variety of peer-reviewed journals and book chapters. Twitter: @shilpaonc Email:guptash@umn.edu

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU CONNECT

GU CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts Independent IME approved

Other programmes of interest

animated-video Animated Video
Oncology 
Elacestrant in ER+/HER2- metastatic breast cancer with ESR1-mut tumors

An overview of the EMERALD subgroup analyses

Experts
Prof. Javier Cortés
  • download Downloadable
    Resources
  • clock 8 MIN
  • calendar Apr 2025

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only.
podcast Podcast
Oncology 
The HER2 diagnostic and treatment landscape in NSCLC: Episode 1

A medical oncologist and a pathologist share their perspectives on best practices in identifying HER2-directed NSCLC

Experts
Prof. Fernando López-Ríos, MD, PhD, Dr Devika Das, Oncology Brothers (Moderators)
Endorsed by
ICAN international cancer advocacy network Biomarker Collaborative Exon20group
  • download Downloadable
    Resources
  • clock 20 MIN
  • calendar Apr 2025

Educational programme supported by an Independent Educational Grant from Bayer.
publication Publication
Oncology 
Survey on the evolving role of the oncology nurse in the USA

Survey findings presented at ONS 2025 and published in the journal Healthcare

Experts
Nina Grenon, Natasha Pinheiro, Karen Waldrop, Brittni Prosdocimo
  • download Downloadable
    Resources
  • clock 7 MIN
  • calendar Apr 2025

Educational programme supported by an Independent Educational Grant from Bayer.
video Video
Oncology 
The patient perspective: Living with NSCLC driven by a rare alteration

What to know, what to expect, and where to find support

Experts
Marcia Horn
Endorsed by
ICAN international cancer advocacy network Biomarker Collaborative Exon20group
BRAF Bombers PD-L1 Amplifieds MET crusaders
  • clock 8 MIN
  • calendar Apr 2025

Educational programme supported by an Independent Educational Grant from Boehringer Ingelheim.
animated-video Animated Video
Oncology 
Chemotherapy strategies for metastatic pancreatic ductal adenocarcinoma

Optimising 1st and 2nd line treatment

Experts
Prof. Eileen O'Reilly, Prof. Efrat Dotan
Endorsed by
ICAN international cancer advocacy network DiCE PanCAN
National Pancreas Foundation
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar Apr 2025

Educational programme supported by an Independent Educational Grant from Ipsen USA.
podcast Podcast
Oncology 
HR+/HER2- metastatic breast cancer: Best practices in molecular testing and targeted therapy

Optimising precision medicine for improved patient outcomes

Experts
Dr Roberto Salgado, Assoc. Clinical Professor Rena Callahan
Endorsed by
ICAN international cancer advocacy network ISLB Exon20group
Biomarker Collaborative
  • download Downloadable
    Resources
  • clock 26 MIN
  • calendar Mar 2025

Educational programme supported by an Independent Educational Grant from Thermo Fisher Scientific.